Drug intelligence / Profile preview

AM2459

Development stage: Preclinical
Lead developer: AMW
Modality: Peptides
Administration: Implant, Subcutaneous

Overview

AM2459 is a preclinical-stage, long-acting, one-month controlled-release biodegradable implant containing leuprolide, a gonadotropin-releasing hormone (GnRH) agonist. Developed by AMW GmbH, the product is intended for the treatment of hormone-sensitive cancers, specifically prostate cancer and breast cancer. The implant utilizes a biodegradable polymer matrix to provide sustained delivery of leuprolide over a 30-day period, aiming to suppress the production of testosterone or estrogen to castrate levels. This formulation is designed to improve patient compliance and therapeutic outcomes compared to traditional injection-based GnRH agonist therapies.

Other names: leuprolideleuprorelin

Targets

GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on AM2459.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM2459.

Explore the full profile